Calcium Channel Blockers Are Associated with Nocturia in Men Aged 40 Years or Older

J Clin Med. 2021 Apr 9;10(8):1603. doi: 10.3390/jcm10081603.

Abstract

Background: The associations of nocturia with hypertension and anti-hypertensive agents (AHTs) remain to be validated.

Methods: This cross-sectional study examined whether blood pressure and/or frequently used classes of AHTs had consistent associations with nocturia.

Methods: A total of 418 male patients aged ≥ 40 years were retrospectively assessed in terms of the International Prostate Symptom Score (IPSS), prescription medications, and blood pressure. Nocturia was evaluated using item 7 of the IPSS, and two or more episodes of nocturia per night was considered to indicate clinically important nocturia.

Results: Patients taking calcium channel blockers (CCBs), but not other AHTs, experienced more episodes of nocturia than patients not taking AHTs (1.77 ± 1.07, 1.90 ± 1.19, and 1.48 ± 0.98 in CCBs alone, CCBs + other AHTs, and other AHTs alone, vs. 1.35 ± 1.08 in not taking AHTs; p = 0.014, p < 0.0001, and p = 0.91, respectively), whereas there was no significant difference in the number of nocturia episodes between patients with elevated and normal blood pressure. In multivariate analysis, CCB (odds ratio (OR) = 2.68, p < 0.0001) and age (OR = 1.06, p < 0.0001) were independently associated with clinically important nocturia.

Conclusion: CCB was associated with nocturia, while AHTs other than CCBs and elevated blood pressure were not.

Keywords: anti-hypertensive agents; blood pressure; calcium channel blocker; hypertension; nocturia.